1 active not recruiting, 1 recruiting, 1 terminated. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Kjer Optic Atrophy: new trials by email Literature Review of Kjer Optic Atrophy trials Research Report on Kjer Optic Atrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy (Myrtle) PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1 / Phase 2 | Recruiting | PYC Therapeutics | 24 | 2025-09-30 | 2026-06-29 |
| SAD of IVT PYC-001 in OPA1 Mutation-Associated Autosomal Dominant Optic Atrophy (Sundew) PYC-001 - OPA1 Gene Mutation, Autosomal Dominant Optic Atrophy | Phase 1 | Active not recruiting | PYC Therapeutics | 18 | 2024-10-31 | 2026-09-17 |
| Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 Mutation Autosomal Dominant Optic Atrophy, Optic Atrophy, Autosomal Dominant | Terminated | PYC Therapeutics | 1 | 2024-02-28 | 2025-03-14 |
Optic Atrophies, Hereditary (3) · Optic Atrophy, Autosomal Dominant (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Cranial Nerve Diseases (3) · Eye Diseases (3) · Eye Diseases, Hereditary (3) · Genetic Diseases, Inborn (3) · Heredodegenerative Disorders, Nervous System (3) · Metabolic Diseases (3) · Mitochondrial Diseases (3) · Nervous System Diseases (3) · Neurodegenerative Diseases (3) · Nutritional and Metabolic Diseases (3) · Optic Atrophy (3) · Optic Nerve Diseases (3)
PYC Therapeutics (3)
Australia (3) · Austria (1) · France (1) · Germany (1) · Netherlands (1) · New Zealand (1) · United States (1)
Aishwarya Kundu (1) · Sreenivasu Mudumba, PhD (1)